Cargando…
Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review
BACKGROUND: Squamous cell carcinoma (SCC) is one of the most common subtypes of non-small cell lung cancer, but its treatment options remain limited. Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) have limited efficacy in the treatment of lung SCC. Here, we report an SCC p...
Autores principales: | Zhang, Zhiqin, Lin, Jiamao, Yang, Linke, Li, Yang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539605/ https://www.ncbi.nlm.nih.gov/pubmed/37781197 http://dx.doi.org/10.3389/fonc.2023.1188772 |
Ejemplares similares
-
Analysis of Prognostic Factors Affecting the Brain Metastases Free Survival and Survival After Brain Metastases in Breast Cancer
por: Xiao, Weikai, et al.
Publicado: (2020) -
Predictors for Long-Term Survival Free from Whole Brain Radiation Therapy in Patients Treated with Radiosurgery for Limited Brain Metastases
por: Gorovets, Daniel, et al.
Publicado: (2015) -
Editorial: Treatment for advanced breast cancer with brain metastases
por: Yan, Min, et al.
Publicado: (2023) -
Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel EGFR Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases
por: Zhi, Xiaoyu, et al.
Publicado: (2021) -
Long-term Survival in a Patient with Recurrent Pulmonary Metastases from Uterine Leiomyosarcoma
por: Garcia, Gwenalyn, et al.
Publicado: (2015)